ProPhase Labs, Inc. (PRPH) Financial Ratios
29 years of historical data (1996–2024) · Healthcare · Drug Manufacturers - Specialty & Generic
EV/EBITDA
↓
N/A
—
5yr avg: 3.98
30Y Low3.1·High80.3
P/FCF
N/A
—
5yr avg: 3.65
30Y Low3.6·High120.7
P/B Ratio
↓
0.36
↓-82% vs avg
5yr avg: 2.07
30Y Low0.8·High184.2
ROE
↓
-188.1%
↑-398% vs avg
5yr avg: -37.8%
30Y Low-188%·High221%
Debt/EBITDA
↓
N/A
—
5yr avg: 0.63
30Y Low0.2·High3.6
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
PRPH Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
ProPhase Labs, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $6M | $14M | $39M | $90M | $66M | $53M | $46M | $72M | $68M | $68M | $49M |
| Enterprise Value | $30M | $38M | $56M | $88M | $72M | $61M | $45M | $70M | $65M | $69M | $49M |
| P/E Ratio → | -0.05 | — | — | 4.73 | 8.97 | — | — | — | 1.68 | — | — |
| P/S Ratio | 0.86 | 2.13 | 0.88 | 0.73 | 0.84 | 3.67 | 4.61 | 5.47 | 6.90 | 3.25 | 2.39 |
| P/B Ratio | 0.36 | 1.96 | 0.79 | 1.41 | 1.13 | 5.04 | 4.06 | 4.35 | 2.14 | 11.46 | 5.57 |
| P/FCF | — | — | — | 3.65 | — | — | — | — | — | — | — |
| P/OCF | — | — | — | 3.15 | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
PRPH EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 5.66 | 1.26 | 0.72 | 0.91 | 4.21 | 4.57 | 5.35 | 6.58 | 3.30 | 2.38 |
| EV / EBITDA | — | — | — | 3.06 | 4.90 | — | — | — | — | — | — |
| EV / EBIT | — | — | — | 3.71 | 11.20 | — | — | — | — | — | — |
| EV / FCF | — | — | — | 3.56 | — | — | — | — | — | — | — |
PRPH Profitability
Margins and return-on-capital ratios measuring operating efficiency
ProPhase Labs, Inc. earns an operating margin of -570.6%. Operating margins have compressed from 19.2% to -570.6% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -188.1% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | -2.2% | -2.2% | 36.6% | 57.6% | 41.5% | 31.7% | 26.5% | 36.4% | 19.7% | 47.9% | 59.1% |
| Operating Margin | -570.6% | -570.6% | -48.7% | 19.2% | 12.4% | -27.4% | -32.8% | -12.4% | -40.4% | -12.6% | -17.4% |
| Net Profit Margin | -788.2% | -788.2% | -37.8% | 15.1% | 7.9% | -14.6% | -31.9% | -13.3% | 423.9% | -13.6% | -17.5% |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -188.1% | -188.1% | -29.7% | 30.2% | 18.1% | -19.5% | -22.7% | -7.2% | 221.3% | -38.8% | -36.8% |
| ROA | -68.8% | -68.8% | -18.7% | 20.9% | 10.4% | -9.7% | -19.1% | -6.3% | 178.1% | -20.8% | -23.3% |
| ROIC | -59.4% | -59.4% | -25.4% | 28.0% | 17.6% | -20.4% | -18.9% | -5.6% | -16.8% | -25.5% | -32.7% |
| ROCE | -75.6% | -75.6% | -30.3% | 32.5% | 19.8% | -21.8% | -23.3% | -6.7% | -20.8% | -32.7% | -34.0% |
PRPH Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $24M ($25M total debt minus $678000 cash).
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 3.34 | 3.34 | 0.37 | 0.11 | 0.25 | 1.39 | — | — | — | 0.25 | 0.17 |
| Debt / EBITDA | — | — | — | 0.24 | 1.01 | — | — | — | — | — | — |
| Net Debt / Equity | — | 3.25 | 0.34 | -0.03 | 0.11 | 0.75 | -0.04 | -0.09 | -0.10 | 0.18 | -0.02 |
| Net Debt / EBITDA | — | — | — | -0.07 | 0.42 | — | — | — | — | — | — |
| Debt / FCF | — | — | — | -0.09 | — | — | — | — | — | — | — |
| Interest Coverage | -11.53 | -11.53 | -16.95 | 30.88 | 8.54 | -13.47 | — | — | -73.89 | -12.47 | -199.11 |
PRPH Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 0.95x is below 1.0, meaning current liabilities exceed current assets. The current ratio has declined from 3.78x to 0.95x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.95 | 0.95 | 2.28 | 3.78 | 3.95 | 2.52 | 10.66 | 4.31 | 15.96 | 1.41 | 2.62 |
| Quick Ratio | 0.92 | 0.92 | 2.17 | 3.54 | 3.65 | 2.04 | 9.10 | 3.86 | 15.11 | 1.01 | 1.66 |
| Cash Ratio | 0.02 | 0.02 | 0.23 | 1.08 | 1.13 | 1.34 | 1.46 | 1.95 | 12.11 | 0.06 | 0.37 |
| Asset Turnover | — | 0.11 | 0.48 | 1.40 | 0.89 | 0.46 | 0.80 | 0.63 | 0.29 | 1.64 | 1.39 |
| Inventory Turnover | 6.05 | 6.05 | 12.29 | 13.08 | 10.05 | 3.26 | 4.98 | 4.39 | 5.17 | 4.00 | 1.95 |
| Days Sales Outstanding | — | 1081.41 | 294.52 | 110.27 | 174.13 | 79.34 | 252.13 | 216.84 | 71.95 | 100.22 | 70.86 |
PRPH Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
ProPhase Labs, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | 10.4% | 6.9% | — | 12.8% | 16.3% | — | — | — |
| Payout Ratio | — | — | — | 50.7% | 72.5% | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | 21.2% | 11.1% | — | — | — | 59.7% | — | — |
| FCF Yield | — | — | — | 27.4% | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 15.3% | 10.7% | 1.4% | 0.0% | 0.0% | 0.0% | 23.9% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 15.3% | 21.1% | 8.3% | 0.0% | 12.8% | 16.3% | 23.9% | 0.0% | 0.0% |
| Shares Outstanding | — | $19M | $17M | $19M | $18M | $12M | $12M | $11M | $16M | $17M | $16M |
Peer Comparison
Compare PRPH with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 PRPHYou | $6M | -0.1 | — | — | -2.2% | -570.6% | -188.1% | -59.4% | — |
 QDEL | $746M | -0.7 | — | — | 46.7% | -33.7% | -46.1% | -13.6% | — |
 CLOV | $1B | -15.8 | — | — | 18.5% | -4.4% | -26.3% | -34.0% | — |
 BNGO | $14M | -0.3 | — | — | 49.4% | -116.9% | -66.2% | -49.1% | — |
 NTRA | $30B | -140.6 | — | 427.2 | 60.3% | -13.1% | -19.4% | -33.3% | — |
 EXAS | $20B | -95.4 | — | 56.1 | 69.7% | -6.4% | -8.7% | -3.6% | — |
 FLGT | $444M | -7.6 | — | — | 40.6% | -28.2% | -5.4% | -6.4% | — |
 CERS | $519M | -31.6 | — | 60.9 | 53.5% | -17.6% | -25.6% | -19.7% | — |
 TMO | $176B | 26.7 | 19.0 | 27.9 | 37.7% | 18.2% | 13.1% | 7.5% | 3.8 |
 DHR | $124B | 34.7 | 18.1 | 23.5 | 60.9% | 20.9% | 7.1% | 5.9% | 2.4 |
 A | $33B | 25.8 | 19.7 | 28.9 | 52.4% | 21.3% | 20.6% | 13.5% | 1.9 |
| Healthcare Median | — | 22.1 | 14.1 | 18.7 | 63.9% | -5.3% | -33.7% | -10.8% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 29 years · Updated daily
See PRPH's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PRPH Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare PRPH vs QDEL
Side-by-side business, growth, and profitability comparison vs QuidelOrtho Corporation.
Start ComparisonPRPH — Frequently Asked Questions
Quick answers to the most common questions about buying PRPH stock.
What is ProPhase Labs, Inc.'s P/E ratio?
ProPhase Labs, Inc.'s current P/E ratio is -0.1x. The historical average is 40.3x.
What is ProPhase Labs, Inc.'s ROE?
ProPhase Labs, Inc.'s return on equity (ROE) is -188.1%. The historical average is -8.7%.
Is PRPH stock overvalued?
Based on historical data, ProPhase Labs, Inc. is trading at a P/E of -0.1x. Compare with industry peers and growth rates for a complete picture.
What are ProPhase Labs, Inc.'s profit margins?
ProPhase Labs, Inc. has -2.2% gross margin and -570.6% operating margin.